Navigation Links
EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations
Date:3/3/2008

Online feedback platform will remain open until March 21, 2008

HOUSTON, March 3 /PRNewswire-USNewswire/ -- Using the same process as government agencies when implementing new policies, a national alliance of scientists, public health leaders, and community representatives today called for public comment on a series of proposals designed to eliminate continued disparities in U.S. clinical trials.

As part of the four year initiative, Eliminating Disparities in Clinical Trials (EDICT), a project jointly conducted by Baylor College of Medicine's Chronic Disease Prevention and Control Research Center and the Intercultural Cancer Council, the alliance created a new Web-based portal so policy makers, patient advocates, research scientists and industry members can review the proposals developed to improve clinical trials patient recruitment and retention in medical research studies. The public comment period closes on March 21, 2008.

On April 1, EDICT will issue its final policy recommendations in Washington, DC.

"A variety of systemic, cultural and psychosocial barriers prevent participation by underrepresented populations, including women, adolescents, older adults, racial and ethnic minorities, those with disabilities, in rural areas and others," said Armin D. Weinberg, Ph.D., Director of Baylor College of Medicine's Chronic Disease Prevention and Control Research Center and EDICT's Principal Investigator.

More than 300 representatives of public, private and non-profit stakeholders catalogued the most significant barriers to participation, examined current policies related to clinical trials, identified opportunities for policy change that would address those barriers, and developed practical and realizable policy solutions to clinical trial disparities at the federal, state and institutional levels in the public, private and non-profit sectors.

"Our policy research has demonstrated the importance of involving the broadest possible set of stakeholders as part of this process. To date, we had input from across all stakeholder groups involved in clinical trials. We are now seeking input from the public at large. We hope that interested individuals and those representing concerned populations will review the policy change recommendations and provide feedback," Weinberg said.

To review the policy recommendations and provide feedback, go to http://www.bcm.edu/edict/policyreview.

EDICT Credo:

-- Everyone should have the opportunity and necessary support to participate voluntarily in clinical trials for which they are eligible.

-- Participants and researchers should understand the benefits of diversity in clinical trials.

-- Results from clinical research should benefit the participants' communities and society at large.

The EDICT (Eliminating Disparities in Clinical Trials) Project was created by Baylor College of Medicine's Chronic Disease Prevention and Control Research Center with the Intercultural Cancer Council and supported by an unrestricted educational grant from Genentech, Inc.


'/>"/>
SOURCE EDICT
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Simple Test Accurately Predicts Risk of Serious Jaundice in Newborns
2. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
3. Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
4. DNA Test Predicts Harmful Effects of Cancer Drug
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio
7. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
8. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
9. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
10. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
11. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):